文献速递肝病

HIV单感染人群中非酒精性脂肪性肝病及纤维化的患病率与特征:系统综述与Meta分析

Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Monoinfection: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2023-01-13

该系统综述与Meta分析纳入43项研究、8230例HIV单感染患者,基于影像学估计非酒精性脂肪性肝病(NAFLD)汇总患病率为33.9%(95%CI 29.67%-38.39%),中度肝纤维化(METAVIR≥F2)为12.00%(95%CI 10.02%-14.12%);基于活检估计非酒精性脂肪性肝炎(NASH)患病率为48.77%(95%CI 34.30%-63.34%),显著肝纤维化(组织学分期≥F2)为23.34%(95%CI 14.98%-32.75%)。传统代谢综合征及HIV相关因素与NAFLD相关。

要点

  • HIV单感染患者中NAFLD汇总患病率为33.9%(95%CI 29.67%-38.39%)。
  • 基于活检的NASH患病率为48.77%(95%CI 34.30%-63.34%)。
  • 传统代谢综合征及HIV相关因素与NAFLD相关。

核心结论

  • 本研究证实HIV单感染人群中NAFLD、NASH及纤维化的疾病负担较高。
  • 需要前瞻性纵向研究以阐明NAFLD、NASH及纤维化的危险因素,并确定该人群NAFLD的早期干预及新疗法。

研究设计与样本

  • 系统综述与随机效应Meta分析,检索PubMed和Embase数据库,纳入报告HIV单感染患者NAFLD和/或纤维化患病率的研究。
  • 共纳入43项研究,报告8230例患者的数据。

主要发现

  • 基于影像学研究,HIV单感染患者NAFLD总体汇总患病率为33.9%(95%CI 29.67%-38.39%)。
  • 基于影像学研究,中度肝纤维化(METAVIR≥F2)汇总患病率为12.00%(95%CI 10.02%-14.12%)。
  • 基于活检研究,NASH患病率为48.77%(95%CI 34.30%-63.34%)。
  • 基于活检研究,显著肝纤维化(组织学分期≥F2)患病率为23.34%(95%CI 14.98%-32.75%)。
  • 传统代谢综合征及HIV相关因素与HIV单感染患者NAFLD相关。

关键数值与推荐

  • NAFLD诊断基于影像学研究,汇总患病率33.9%(95%CI 29.67%-38.39%)。
  • 中度肝纤维化定义为METAVIR≥F2,基于影像学研究汇总患病率12.00%(95%CI 10.02%-14.12%)。
  • NASH诊断基于活检研究,汇总患病率48.77%(95%CI 34.30%-63.34%)。
  • 显著肝纤维化定义为组织学分期≥F2,基于活检研究汇总患病率23.34%(95%CI 14.98%-32.75%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要前瞻性纵向研究以阐明NAFLD、NASH及纤维化的危险因素,并确定该人群NAFLD的早期干预及新疗法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Liver disease remains a leading cause of morbidity and mortality among people living with HIV (PLWH). Emerging data suggest that PLWH are at high risk for developing nonalcoholic fatty liver disease (NAFLD). The aim of this review is to examine the current literature and provide an accurate estimate of the prevalence of NAFLD, nonalcoholic steatohepatitis (NASH), and fibrosis, and identify potential risk factors for NAFLD in PLWH. METHODS: We searched PubMed and Embase databases to identify studies reporting the prevalence of NAFLD and/or fibrosis in PLWH monoinfection. We performed a random effects meta-analysis of proportions to estimate the pooled prevalence of NAFLD, NASH, and fibrosis among PLWH monoinfection. We also examined potential risk factors for NAFLD by comparing characteristics of PLWH monoinfection with and without NAFLD. RESULTS: A total of 43 studies, reporting data for 8230 patients, met our eligibility criteria and were included in the meta-analysis. Based on imaging studies the overall pooled prevalence of NAFLD and moderate liver fibrosis (METAVIR ≥ F2) among PLWH monoinfection was 33.9% (95% confidence interval [CI], 29.67%-38.39%), and 12.00% (95% CI, 10.02%-14.12%), respectively. Based on biopsy studies, prevalence of NASH and significant liver fibrosis (stage ≥F2 on histology) was 48.77% (95% CI, 34.30%-63.34%) and 23.34% (95% CI, 14.98%-32.75%), respectively. Traditional metabolic syndrome and HIV-related factors were associated with NAFLD in PLWH. CONCLUSIONS: Our study confirms that the burden of NAFLD, NASH, and fibrosis is high among PLWH monoinfection. Prospective longitudinal studies are needed to delineate NAFLD, NASH, and fibrosis risk factors, and identify early interventions and new therapies for NAFLD in this population.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kalligeros M, Vassilopoulos A, Shehadeh F, et al. Prevalence and Characteristics of Nonalcoholic Fatty Liver Disease and Fibrosis in People Living With HIV Monoinfection: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023. PMID: 36642292. doi:10.1016/j.cgh.2023.01.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。